



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMADOC-1700519818-1859783

European Medicines Agency decision

EMA/PE/0000225594

of 28 January 2025

on the acceptance of a modification of an agreed paediatric investigation plan for imlifidase (Idefirix) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

EMA/PE/0000225594

of 28 January 2025

on the acceptance of a modification of an agreed paediatric investigation plan for imlifidase (Idefirix) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0229/2018 issued on 30 July 2018 and the decision P/0076/2022 issued on 11 March 2022,

Having regard to the application submitted by Hansa Biopharma AB on 04 September 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 December 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for imlifidase (Idefirix), including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Hansa Biopharma AB, Scheelevagen 22, Lunds Allhelgonafors., 223 63 - Lund Skane Lan, Sweden.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMADOC-1700519818-1695559
Amsterdam, 13 December 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA/PE/0000225594

Scope of the application

Active substance(s):

Imlifidase

Invented name and authorisation status:

See Annex II

Condition(s):

Prevention of graft rejection following solid organ transplantation

Pharmaceutical form(s):

Powder for concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Hansa Biopharma AB

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Hansa Biopharma AB submitted to the European Medicines Agency on 4 September 2024 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0229/2018 issued on 30 July 2018 and the decision P/0076/2022 issued on 11 March 2022.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 14 October 2024.



Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Paediatric Committee members of Liechtenstein and Norway agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Prevention of graft rejection following solid organ transplantation

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- powder for concentrate for solution for infusion, intravenous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Prevention of graft rejection following solid organ transplantation

2.1.1. Indication(s) targeted by the PIP

Pre-transplant treatment to make patients with donor specific IgG eligible for kidney transplantation

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 year to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	Study 1 Open-label, non-randomised, exploratory trial to evaluate efficacy of IdeS in creating a negative crossmatch test in children from 1 year to less than 18 years of age who are planned to undergo kidney transplantation.
Extrapolation, modelling and simulation studies	Study 2 Extrapolation study to evaluate the use of IdeS in children from 1 year to less than 18 years of age who are planned to undergo kidney transplantation.

Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By March 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Prevention of graft rejection following solid organ transplantation

Authorised indication(s):

Idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. The use of Idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

- Invented name(s): Idefirix 11 mg
- Authorised pharmaceutical form(s): Powder for concentrate for solution for infusion (powder for concentrate)
- Authorised route(s) of administration: Intravenous use
- Authorised via centralised procedure